Innovation as Strategy

Five years ago, P.S.S. Urology was a distributor.  A very good one, but a distributor, nonetheless.  It was not a mistake or a missed opportunity.  It was a canvas.  It gave us market access, physician relationships, supply chain infrastructure, and credibility in a niche where trust matters enormously.  That foundation was essential.  I’m grateful to everyone who built it.

But standing in that distributor model, I saw something that troubled me: the innovation gap in urology was real.  The broader electrosurgical market was even more starved.  And the implications were clear.  Physicians were managing their day to day with tools that hadn’t fundamentally changed in years, despite the fact that the physics and materials science underlying electrosurgery are far more sophisticated than most clinicians realize.  We were operating at the edge of physics and materials science, yet the market was accepting incremental thinking as innovation.

That’s where the work began.

I’ve spent over 30 years designing products, manufacturing processes and machines, and entire factories across diverse industries including automotive, defense, aerospace, solar power, and medical devices.  In every sector, I learned the same lesson: innovation isn’t about breakthrough moments.  It’s about taking the time to understand the real problem, talking to the people who live with it every day, and then applying disciplined engineering to create something that is not just novel, but genuinely useful, reliable, and economical.

Electrosurgery is misunderstood.  It’s often treated as a commodity and a supporting player in procedural suites. But physics is demanding.  The materials science landscape is complicated.  A precision electrode that works reliably at the cellular level, that heats tissue at exactly the right rate, that minimizes collateral damage, that remains affordable, and that physicians can use intuitively…that’s not commodity work.  That’s engineering, materials science, and physics.

When I arrived at P.S.S., I realized that this gap between the sophistication of the science and the maturity of the market was an opportunity.  Not for innovation theater, the kind where companies announce features and hope physicians like them.  Real opportunity: solving genuine clinical problems that physicians had been flagging for years but had accepted as unsolvable.

Over the past five years, we’ve developed a structured approach to innovation that reflects what I’ve learned across industries and what the medical device space demands.

Physician input first: We spend time in procedural suites.  We listen.  We understand the friction points, what’s clumsy, what’s dangerous, what’s inefficient.  This isn’t a survey; it’s embedded collaboration.  Physicians are the stewards of patient safety.  Their insights are gold. They live the complexities and successes daily.

Engineering and Prototyping: We take that insight and translate it into materials science, physics, and design. We prototype, test, and iterate.  We fail.  We learn, and we fail smarter.

Market and Regulatory Reality: Simultaneously, we assess the market landscape and map the regulatory pathway.  FDA clearance is not an afterthought; it’s woven into the design from day one.  We’ve learned that companies that treat regulatory strategies as separate from product strategy end up with delays, compromises, and products that don’t reflect their original design.

Manufacturing and Supply Chain Readiness:  An innovative concept means nothing if you can’t manufacture it reliably at scale and affordably.  This is where materials science, process engineering, and quality systems converge.  We design for manufacturing.  We validate supply chains.  We stress-test our quality systems before we need them.

Distribution and Market Adoption: Finally, we ensure physicians can access these solutions, and that hospital supply chains can integrate them seamlessly.

This isn’t a linear process; it’s parallel and iterative.  It’s the opposite of hope-based product development.

Our UltraThin electrodes exemplify this methodology.  They began with physician feedback collected over the years using observations from urologists working in challenging anatomies, constrained spaces, and precision-critical procedures.  The clinical insight was clear: existing electrode geometries had geometric and material limitations that forced procedural compromises.

We took that insight and asked: what does materials science and precision manufacturing allow us to achieve? Can we create an electrode that is mechanically sound, thermally predictable, and safe to use at the dimensions required?  And can we do the necessities affordably?

The answer required deep work in materials selection, electrode geometry, manufacturing precision, and testing protocols.  Materials engineers, manufacturing specialists, quality experts, and regulatory professionals spent months validating that this wasn’t just theoretically possible, but clinically safe and manufacturable at scale.

Today, The P.S.S. Ultrathin Electrodes are becoming the electrode of choice for certain urology procedures.  That outcome isn’t luck.  It’s the result of listening, engineering rigorously, validating exhaustively, and refusing to cut corners.  We’re publishing a deeper analysis of what makes UltraThin work the way it does in an article that will be available soon.

This is the point: That’s our process.  That’s how we work now.

Here’s what matters to physicians, hospital supply chains, and investors: P.S.S. has become something rare in MedTech.

We are in-market and profitable.  Most MedTech startups live in a burn-rate story: fundraising, runway, with hope as a strategy.  We’re not.  We generate revenue.  We’re disciplined about cost.  We reinvest in innovation from cash flow.

We are fully FDA-compliant and agile.  We understand regulatory requirements not as bureaucratic obstacles but as expressions of serious commitment to safety.  We’ve built processes that satisfy FDA rigor without strangling our ability to iterate.  That’s genuinely hard and many companies get it wrong.

We are a platform, not a product.  We have the expertise, the manufacturing infrastructure, the supply chain relationships, the FDA clearance pathways, the distribution network, and – critically – physician trust.  We have solved the hard problems that many innovative companies cannot: the regulatory barriers, the physician acceptance hurdle, the manufacturing complexity, and the profitability equation.

The platform is our real asset.  It doesn’t show up on a balance sheet.  But it is what drives value for customers and shareholders.

‍

The Opportunity Ahead

Here’s what excites me about where we are: P.S.S. has  built something that can accelerate innovation in electrosurgery and related fields.

There are innovators out there, physicians, engineers, and researchers who have genuine ideas for solving real clinical problems.  They have technical insights.  They have a market understanding.  What often lacks is the infrastructure to native FDA pathways, to validate safety rigorously, to scale manufacturing, to manage supply chains, to reach physicians, and to be profitable while doing it.

We can be that partner.  We can take promising innovation and shepherd it through the gauntlet.  We have expertise, regulatory pathways, manufacturing readiness, and distribution. Most startups cannot navigate this alone.  That’s what a platform does.

‍

Who We Are

To physicians, we’re not another vendor trying to sell you something you don’t need.  We’re listening to your procedural challenges, your safety concerns, and your efficiency goals.  We’re engineers and quality experts who care about outcomes as much as you do.  We’re built for collaboration.

To the hospital supply chain, we’re agile, responsive, and profitable.  This means we are sustainable.  We’re not burning cash waiting for an exit.  We are inventing complicated contract terms.  We're investing in long-term relationships and continuous improvement.

To investors, we aren’t a story or a pitch.  We’re an infrastructure.  We have validated a model that most MedTech companies struggle to achieve profitable, compliant, agile, physician-trusted, and positioned to accelerate innovation in a market that needs it.  That’s rare.  That’s valuable.

Five years ago, we were a canvas.  Today, we’re a platform.  The work is just beginning.